Larimar Therapeutics (LRMR) Non-Current Debt (2014 - 2020)

Larimar Therapeutics (LRMR) has reported Non-Current Debt for 7 consecutive years, with $6.7 million the latest figure, recorded in Q1 2020.

• For the quarter ending Q1 2020, Non-Current Debt fell 50.12% year-over-year to $6.7 million; the trailing twelve-month figure through Mar 2020 stood at $6.7 million (down 50.12% YoY), and the FY2019 full-year result was $8.5 million, down 44.26% from the prior year.
• Non-Current Debt eased to $6.7 million in Q1 2020 per LRMR's latest filing, from $8.5 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $20.5 million in Q3 2018 and bottomed at $1.2 million in Q3 2016.
• Historically, Non-Current Debt has averaged $11.8 million across 5 years, with a median of $11.9 million in 2019.
• The sharpest annual moves came in 2016 and 2018: Non-Current Debt slumped 73.69% in 2016, then decreased 24.08% in 2018.
• Over 5 years, Non-Current Debt stood at $1.2 million in 2016, then jumped by 1566.67% to $20.0 million in 2017, then dropped by 24.08% to $15.2 million in 2018, then plunged by 44.26% to $8.5 million in 2019, then retreated by 20.29% to $6.7 million in 2020.
• According to Business Quant data, Non-Current Debt over the past three periods registered $6.7 million, $8.5 million, and $10.2 million for Q1 2020, Q4 2019, and Q3 2019 respectively.